<DOC>
	<DOC>NCT00605241</DOC>
	<brief_summary>GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will asses the effects of a single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male volunteers who smoke. Each cohort of subjects will receive a single dose of placebo or GSK598809 in two dosing sessions binded crossover fashine. There will be a washout period of at least seven days between each session.</brief_summary>
	<brief_title>A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy male smokers aged 1865 with a desire to quit smoking. Body weight greater than 50kg and BMI within range 19 29.9 kg/m2 Healthy with no significant medical, psychiatric or laboratory evaluation abnormality. Positive prestudy urine drug/breath alcohol screen: positive HIV 1/2, Hepatitis B or Hepatitis C test at screening. History of alcohol/drug abuse or dependence (other than nicotine) within 12 months of the study. History of psychiatric disorder or sensitivity to any of the study medications or components thereof or a history of drug or allergy that in the opinion of the physician responsible contraindicates their participation. History of cardiac or pulmonary disease/abnormalities.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pharmacodynamics,</keyword>
	<keyword>pharmacokinetics,</keyword>
	<keyword>tolerability,</keyword>
	<keyword>Safety,</keyword>
	<keyword>single dose,</keyword>
	<keyword>placebo,</keyword>
	<keyword>Nicotine reward</keyword>
	<keyword>GSK598809</keyword>
</DOC>